(Q83642554)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19364456%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

title

Monoclonal antibody treatments for multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19364456%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

John W Rose

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19364456%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

John F Foley

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19364456%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Noel G Carlson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19364456%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

publication date

1 May 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19364456%20AND%20SRC:MED&resulttype=core&format=json

Current treatment options in neurology

25 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19364456%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19364456%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19364456%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

211-220

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19364456%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11940-009-0025-5

25 January 2020

exact match

0 references

cites work

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

1 reference

12 December 2020

Melanoma complicating treatment with natalizumab for multiple sclerosis

1 reference

12 December 2020

Toward the development of rational therapies in multiple sclerosis: what is on the horizon?

1 reference

12 December 2020

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

1 reference

12 December 2020

Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis

1 reference

12 December 2020

FDA advisers endorse natalizumab for Crohn's disease

1 reference

12 December 2020

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

12 December 2020

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

1 reference

12 December 2020

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial

1 reference

12 December 2020

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

1 reference

12 December 2020

1 reference

12 December 2020

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

1 reference

12 December 2020

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

12 December 2020

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

12 December 2020

Replacing the complementarity-determining regions in a human antibody with those from a mouse

1 reference

12 December 2020

Rituximab in a patient with multiple sclerosis--effect on B cells, plasma cells and intrathecal IgG synthesis

1 reference

12 December 2020

Chimeric cytotoxin IL2-PE40 inhibits relapsing experimental allergic encephalomyelitis

1 reference

12 December 2020

Autoimmune effector cells. IX. Inhibition of adoptive transfer of autoimmune encephalomyelitis with a monoclonal antibody specific for interleukin 2 receptors

1 reference

12 December 2020

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

1 reference

12 December 2020

A humanized antibody that binds to the interleukin 2 receptor

1 reference

12 December 2020

1 reference

12 December 2020

Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series

1 reference

12 December 2020

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Advances in interleukin 2 receptor targeted treatment

1 reference

12 December 2020

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

1 reference

12 December 2020

An open label study of the effects of rituximab in neuromyelitis optica

1 reference

12 December 2020

How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis

1 reference

12 December 2020

Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions

1 reference

12 December 2020

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

1 reference

12 December 2020

CAMPATH-1H in multiple sclerosis

1 reference

12 December 2020

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

1 reference

12 December 2020

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

1 reference

12 December 2020

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

12 December 2020

Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis

1 reference

12 December 2020

Immunotherapy of experimental autoimmune encephalomyelitis (EAE): Differential effect of anti-IL-2 receptor antibody therapy on actively induced and T-line mediated EAE of the Lewis rat

1 reference

12 December 2020

Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

1 reference

12 December 2020

Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy

1 reference

12 December 2020

The B cell--old player, new position on the team

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

The potential utility of B cell-directed biologic therapy in autoimmune diseases

1 reference

12 December 2020

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

1 reference

12 December 2020

Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production

1 reference

12 December 2020

Risk alleles for multiple sclerosis identified by a genomewide study

1 reference

12 December 2020

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

1 reference

12 December 2020

Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used.

1 reference

12 December 2020

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

12 December 2020

Treatment of patients with the hypereosinophilic syndrome with mepolizumab

1 reference

12 December 2020

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

1 reference

12 December 2020

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

1 reference

12 December 2020

Treating multiple sclerosis with monoclonal antibodies

1 reference

12 December 2020

A controlled trial of natalizumab for relapsing multiple sclerosis.

1 reference

12 December 2020

1 reference

12 December 2020

Rituximab: expanding role in therapy for lymphomas and autoimmune diseases

1 reference

12 December 2020

10.1007/S11940-009-0025-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19364456%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference